By FieldPulse Staff · March 18, 2026
Tags: strategy, leadership
Reuters analysis finds ~1 in 3 TrumpRx drugs still cost more than in the UK. Program is voluntary with no enforcement, and political opposition to MFN legislation is growing.
A Reuters analysis published March 18, 2026 found that approximately one-third of the 54 drugs listed on TrumpRx.gov — the White House drug pricing platform launched earlier this year — remain more expensive than what patients pay in the United Kingdom, even after voluntary discounts offered by participating manufacturers. Among the drugs still priced higher than UK equivalents: Pfizer's Xeljanz (JAK inhibitor), AstraZeneca's Farxiga (SGLT2 inhibitor), and several GSK inhalers, which are 67–82% cheaper in Britain. Critics including Harvard's Aaron Kesselheim noted the program is entirely volun